First half of 2017: New record sales and a solid operating result
August 25, 2017 at 09:53 am IST
Share
Sales and EBIT further increased
EBITDA at 26.6% and EBIT at 17.9% of sales
Net profit affected by currency effects
Capacity expanded and new jobs created
Stronger second semester expected
Fiscal 2017 expected to be a very good year
Full-year guidance confirmed
Bubendorf/Basel, August 25, 2017 - Bachem Group (SIX: BANB) increased its sales in the first half of 2017 by 5.3% to a new record high of 119.5 million CHF (H1 2016: 113.4 million CHF). In contrast to the previous year, exchange rate movements did not have a relevant impact on the translation of local sales, which were up by 5.2% year-on-year. Generics sales reached 52.0 million CHF and were slightly below the very strong level achieved during the prior year period (53.9 million CHF). There were promising developments in the research ingredients product line. Catalog peptides and custom synthesis products performed well in the face of a challenging, highly competitive market environment. Bachem's New Chemical Entities (NCEs) product line delivered outstanding results again, with sales advancing about 24% year-on-year. Despite some project delays and temporarily reduced cost absorption due to capacity expansions, operating profit increased to 31.7 million CHF at the EBITDA level and to 21.4 million CHF at the EBIT level. Currency translation effects of -2.7 million CHF had a clearly negative impact on net profit for the first half 2017. This is largely attributed to the valuation at the balance sheet date of USD loans granted to subsidiaries by the holding company. Due to this negative effect, net profit for the period came in at 15.8 million CHF (H1 2016: 17.1 million CHF).
Press Release
Bachem Holding AG published this content on 25 August 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 25 August 2017 04:22:01 UTC.
Original documenthttp://www.bachem.com/news-media/press-releases/detail/article/first-half-of-2017-new-record-sales-and-a-solid-operating-result/
Public permalinkhttp://www.publicnow.com/view/CC4CDA96767BB1B2E772FC38D0C79E23CE865530
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.